Research Profiles

Scientific Discovery

Vern L. Schramm, Ph.D.

Dismantling Disease: Drug Development to Block Enzymes

Vern Schramm, Ph.D., has pioneered a technology for identifying highly potent inhibitors of enzymes that play key roles in human diseases. Using this technology, he has developed enzyme-inhibiting drugs now being tested by Einstein licensees in phase 2 clinical trials for T cell lymphoma and gout. Other clinical-trial candidates are drugs developed by Dr. Schramm that target malaria, head and neck cancer, and antibiotic-resistant bacteria. Dr. Schramm was elected to the National Academy of Sciences in 2007 and is professor and chair of the biochemistry department and the Ruth Merns Chair in Biochemistry.


Other Top Einstein Researchers